Literature DB >> 25572406

The impact of CRISPR-Cas9 on target identification and validation.

Jonathan D Moore1.   

Abstract

The addition of an RNA-guided nuclease, Cas9, to the gene editing toolbox has increased the accessibility of gene editing technologies by greatly simplifying the design of editing reagents. Only a single 75-100 nucleotide RNA is required to guide Cas9 to the target gene of interest, which has meant that the established infrastructure of short-hairpin RNA interference screen could be readily adapted to genome-wide knock out screens. Cas9-based editing technology should streamline the generation of animal and cell-line models, make the generation of activity-dead mutations in target validation routine, and enable the discovery of a new generation of targets across therapeutic areas.
Copyright © 2015. Published by Elsevier Ltd.

Mesh:

Substances:

Year:  2015        PMID: 25572406     DOI: 10.1016/j.drudis.2014.12.016

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  16 in total

1.  Target (In)Validation: A Critical, Sometimes Unheralded, Role of Modern Medicinal Chemistry.

Authors:  Ramzi F Sweis
Journal:  ACS Med Chem Lett       Date:  2015-05-21       Impact factor: 4.345

2.  Come together, right now….

Authors:  Herman Yeger
Journal:  J Cell Commun Signal       Date:  2015-07-25       Impact factor: 5.782

Review 3.  Opportunities and challenges in phenotypic drug discovery: an industry perspective.

Authors:  John G Moffat; Fabien Vincent; Jonathan A Lee; Jörg Eder; Marco Prunotto
Journal:  Nat Rev Drug Discov       Date:  2017-07-07       Impact factor: 84.694

Review 4.  Screening out irrelevant cell-based models of disease.

Authors:  Peter Horvath; Nathalie Aulner; Marc Bickle; Anthony M Davies; Elaine Del Nery; Daniel Ebner; Maria C Montoya; Päivi Östling; Vilja Pietiäinen; Leo S Price; Spencer L Shorte; Gerardo Turcatti; Carina von Schantz; Neil O Carragher
Journal:  Nat Rev Drug Discov       Date:  2016-09-12       Impact factor: 84.694

5.  Monoclonal Cell Line Generation and CRISPR/Cas9 Manipulation via Single-Cell Electroporation.

Authors:  Ruiguo Yang; Vincent Lemaître; Changjin Huang; Abbas Haddadi; Rebecca McNaughton; Horacio D Espinosa
Journal:  Small       Date:  2018-02-12       Impact factor: 13.281

6.  Open PHACTS computational protocols for in silico target validation of cellular phenotypic screens: knowing the knowns.

Authors:  D Digles; B Zdrazil; J-M Neefs; H Van Vlijmen; C Herhaus; A Caracoti; J Brea; B Roibás; M I Loza; N Queralt-Rosinach; L I Furlong; A Gaulton; L Bartek; S Senger; C Chichester; O Engkvist; C T Evelo; N I Franklin; D Marren; G F Ecker; E Jacoby
Journal:  Medchemcomm       Date:  2016-05-11       Impact factor: 3.597

7.  Phospholamban Ablation Using CRISPR/Cas9 System Improves Mortality in a Murine Heart Failure Model.

Authors:  Manami Kaneko; Kentarou Hashikami; Satoshi Yamamoto; Hirokazu Matsumoto; Tomoyuki Nishimoto
Journal:  PLoS One       Date:  2016-12-16       Impact factor: 3.240

8.  A Medium-Throughput Single Cell CRISPR-Cas9 Assay to Assess Gene Essentiality.

Authors:  A R Grassian; T M E Scales; S K Knutson; K W Kuntz; N J McCarthy; C E Lowe; J D Moore; R A Copeland; H Keilhack; J J Smith; J A Wickenden; S Ribich
Journal:  Biol Proced Online       Date:  2015-11-14       Impact factor: 3.244

9.  Identification of oncogenic driver mutations by genome-wide CRISPR-Cas9 dropout screening.

Authors:  Michael K Kiessling; Sven Schuierer; Silke Stertz; Martin Beibel; Sebastian Bergling; Judith Knehr; Walter Carbone; Cheryl de Vallière; Joelle Tchinda; Tewis Bouwmeester; Klaus Seuwen; Gerhard Rogler; Guglielmo Roma
Journal:  BMC Genomics       Date:  2016-09-09       Impact factor: 3.969

10.  Increasing the performance of pooled CRISPR-Cas9 drop-out screening.

Authors:  Benedict C S Cross; Steffen Lawo; Caroline R Archer; Jessica R Hunt; Joanne L Yarker; Alessandro Riccombeni; Annette S Little; Nicola J McCarthy; Jonathan D Moore
Journal:  Sci Rep       Date:  2016-08-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.